^
Association details:
| Biomarker: | TP53 Y220C |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | rezatapopt (PC14586) (p53 reactivator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB006 - PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development
Published date:
04/09/2021
Excerpt:
...mice bearing Y220C mutant NUGC3 gastric cancer xenograft tumors, oral administration of PC14586 results in a dose responsive anti-tumor effect, with a target efficacious dose of 100 mg/kg daily resulting in approximately 80% tumor regression after 3 weeks.
